Children with autism spectrum disorder (ASD) exhibited significantly higher urinary concentrations of microbially derived metabolites compared to typically developing controls. The study achieved 90% sensitivity and 100% specificity in classifying ASD based on metabolite levels.
Background
Autism spectrum disorder (ASD) is a neurodevelopmental disorder marked by social communication deficits and repetitive behaviors. Early identification is critical for improving outcomes, yet current diagnostic practices rely on behavioral assessments rather than biological markers. This study explores the potential of urinary metabolites as a novel biomarker for ASD.
Data Highlights
Metabolite
ASD Group Concentration
Control Group Concentration
Difference
p-cresol
151% higher
Baseline
151%
methyl-3-indole acetate
1,882% higher
Baseline
1,882%
arabinitol
89% higher
Baseline
89%
Key Findings
Children with ASD had an average MDM total score of 3.3, while typically developing children scored zero.
Ninety percent of children with ASD had at least one markedly elevated metabolite.
Twenty-three out of 24 selected metabolites were significantly elevated in the ASD group.
The MDM System achieved 78% sensitivity and 100% specificity in validation.
Metabolite elevations varied among children with ASD, indicating heterogeneity in the disorder.
Clinical Implications
The findings indicate that urinary metabolite profiling may assist in identifying children with ASD.
Conclusion
This pilot study highlights the differences in microbially derived urinary metabolites between children with ASD and typically developing controls.
